Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01712477
Other study ID # r039226
Secondary ID IRRC#1201M
Status Terminated
Phase Phase 4
First received
Last updated
Start date November 2011
Est. completion date December 2014

Study information

Verified date May 2018
Source Michigan State University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a prospective randomized controlled pilot study in traumatic brain injury (TBI) patients who are sedated with either propofol or midazolam to compare the cytokine response and neuropsychological outcomes with and without elevated blood alcohol levels.

Sedation is part of the standard treatment in patients with a TBI and has been proposed as a neuroprotective intervention in head-injured patients. Sedative regimens, such as midazolam and propofol, are not standardized and it is unclear whether sedation has a significant impact on recovery and outcome. A review of propofol versus midazolam in mechanically ventilated patients shows evidence that both provide effective sedation but there is lack of data to support one sedative over the other.

Cytokines are released in response to tissue injury and act to generate a variety of physiologic responses. The cytokine elevation has been correlated with the extent of tissue injury. This study will compare the cytokine distribution patterns at specific posttraumatic time points in patients with a TBI sedated with either propofol or midazolam. Additional analysis will compare the cytokine response in patients whom had elevated blood alcohol levels with those with normal levels. Neuropsychological testing will also be performed to determine the extent of brain injury and recovery.


Description:

The purpose of this research is to compare the effectiveness, length of time from cessation of sedation till extubation, recovery time, duration of admission to the ICU, recovery of brain function, cytokine response, and complication rate of propofol versus midazolam when used for sedation in patients with traumatic brain injury (TBI) with or without elevated blood alcohol levels. Since this type of trauma patient will require significant medical care upon admission to the emergency room (ER) and the family will be concerned about the injuries, the patient and/or family will not be approached about the research study during this time. At the earliest possible time following neurointensive (NICU) or intensive care (ICU) admission, an informed consent will be obtained from the patient. Depending on the severity of the head injury, the patients may not be able to sign an informed consent. In this case, the consent will be obtained from next-of-kin or a legal guardian. No interventions or study research will be conducted on the patient until the consent is obtained.

Standard blood panels are drawn for every trauma patient regardless of whether or not the patient is a participant of the research protocol, including blood alcohol levels. During the trauma workup in ER, it is standard of care to draw an extra vial in case additional lab tests are needed. After consent is obtained, the research team will obtain the extra vial from the Sparrow Lab to perform cytokine and blood cell phenotype measurements for the research study. Typically 0.5-1.0 ml of whole blood is needed for these measurements and that can be taken from the standardized EDTA tube that is drawn on admission. This small amount of blood sample would otherwise be discarded. Plasma cytokines and cell phenobype IL-1, IL-3, IL-6, IL-8, IL-10, IL-17, TNF-¦Á, TGF-¦Â, G-CSF, GM-CSF, SCF, FGF, and IGF-II will be performed by Luminex-based mutiplex assay and ELISA. In addition to the ER analysis, left over blood will be used from the EDTA tubes at 24 hours, day 3 and day 7 after admission. These additional measurements will be taken from the routine morning laboratory blood draws which are done on all intubated patients to evaluate electrolytes. No additional blood will be drawn for the research and the study will only be using left over blood already drawn for standard of care labs that are done on all intubated patients.

Once consented, the patients will be randomized to treatment group by random allocation process using Research Randomizer (Urbaniak, G. C., & Plous, S. Version 3.0 Computer software]. The patient and family will be blinded to which sedation is given. Nurses and physicians will not be blinded as they will be administering the sedatives. Although the patients will receive randomized sedation, these patients would be administered either propofol or midazolam even if they were not included in this research. The only modification for research purposes is the randomization of sedation medication by the randomizer rather than the physician. Currently, the providers in the research team do not have a preference of one type of sedation medication over the other.

Once randomized, patients allocated to the propofol group will be initiated with a 0.5-1 mg/kg i.v. bolus followed by repeated 10-20 mg doses at variable intervals (approximately 15 s, at the discretion of the physician/nurse) until an appropriate level of sedation will be achieved (NICU protocol), which will be subsequently titrated to achieve a target Richmond Agitation-Sedation Scale (+4 = combative to -5 = unarousable) (Sessler et al. The Richmond Agitation-Sedation Scale.Am J Respir Crit Care Med 2002; 166:1338-1344). Nurses will note pre-sedation levels based on the Richmond Agitation-Sedation Scale. While undergoing sedation, target sedation will be defined when the Richmond Agitation-Sedation Scale meets a score of -4 to -5. Patients randomized to the midazolam group will be initiated with 0.5-1.0 mg with incremental dosing at intervals of approximately 1-3 min until a level of sedation will be achieved at a target Richmond Agitation-Sedation scale sedation score (per NICU protocol).

Management of all trauma patients include a careful history taking for alcoholism with referral for further evaluation or treatment when indicated, and determination whether other drugs are also being used. All patients with an elevated alcohol level require a medical social service consultation and all patients with a TBI require a neuropsychology consultation, both consultations are standard of care. The neuropsychological testing conducted after extubation is also standard of care. The neuropsychological evaluations will be measured based on the following assessments: intellectual functioning, language processing, visuospatial processing, attention, concentration, verbal learning, memory, executive functioning, sensory, perception, motor, strength, and personal assessment. The level of impairment will be based on a scale from zero to seven. Data will be collected until the patient is discharged from the hospital. The clinical records from the neuropsychologist will be reviewed to analyze the progression of the patient's outcome. Similar to all trauma patients, the patients enrolled in this study will be offered continued care with neuropsychology as well as the option to withdrawal all care if competent to make independent decisions.

Throughout the study consciousness will be measured using the Glasgow Coma Score (GCS) from the time of presentation to the ER and two times each day until the patient is discharged from the NICU or ICU (routinely done on TBI patients). The Injury severity scores (ISS) will be recorded from admission (done on all trauma patients). Recovery of consciousness will be determined by measurement of the acute physiology and chronic health evaluation (APACHE) III modification of the Glasgow coma score to allow for scoring of the verbal component in intubated patients. Patients will be judged to be awake when the Glasgow coma score was > or = 12.

The following will be recorded from the Sparrow medical record for each patient: gender, age, sex, weight, primary diagnosis, significant co morbidities, blood alcohol level at admission, intracranial pressure measurements (standard of care for TBI patients), time of starting and finishing of the sedation, total amount of medications given, any restraint required, additional oxygen required, resuscitative measures required, time of transfer out of the unit, and time of discharge.


Recruitment information / eligibility

Status Terminated
Enrollment 1
Est. completion date December 2014
Est. primary completion date November 2014
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Ages 18 Years or older

- Males or Females

- Primary diagnosis of TBI, subarachnoid hemmorhage (SAH), intracranial hemmorhage (ICH), stroke

- Requires mechanical ventilation

- Requires or is receiving continuous IV sedation

Exclusion Criteria:

- Glascow Coma Score (GCS) of 3 persisting from the scene with bilaterally fixed dilated pupils with no appreciable chance of survival

- The inability to identify a next of kin or guardian to give consent if patient unable to consent

- Pregnant

- Allergy or contraindication to propofol

- Allergy to contraindication to midalozam

- Status epilepticus

- Current neuromuscular blockade

- Patient with a known hypersensitivity to propofol or midalozam

- Allergies to eggs, egg products, soybeans or soy products

- Acute narrow-angle glaucoma

Study Design


Intervention

Drug:
Intravenous sedation using propofol
Patients will be given intravenous sedation for treatment of traumatic brain injury requiring mechanical ventilation
Intravenous sedation with midazolam
patients with severe traumatic brain injury requiring mechanical ventilation and sedation will be sedated with midazolam

Locations

Country Name City State
United States Sparrow Health System Lansing Michigan

Sponsors (1)

Lead Sponsor Collaborator
Michigan State University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Neuropsychgologic outcome Extent of functional deficits from underlying traumatic brain injury 30 days
Secondary cytokine levels correlating to extent of injury cytokine levels will be measured to see if there is meaningful correlation between groups 30 days
See also
  Status Clinical Trial Phase
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Recruiting NCT05503316 - The Roll of Balance Confidence in Gait Rehabilitation in Persons With a Lesion of the Central Nervous System N/A
Completed NCT04356963 - Adjunct VR Pain Management in Acute Brain Injury N/A
Completed NCT03418129 - Neuromodulatory Treatments for Pain Management in TBI N/A
Terminated NCT03698747 - Myelin Imaging in Concussed High School Football Players
Recruiting NCT05130658 - Study to Improve Ambulation in Individuals With TBI Using Virtual Reality -Based Treadmill Training N/A
Recruiting NCT04560946 - Personalized, Augmented Cognitive Training (PACT) for Service Members and Veterans With a History of TBI N/A
Completed NCT05160194 - Gaining Real-Life Skills Over the Web N/A
Recruiting NCT02059941 - Managing Severe Traumatic Brain Injury (TBI) Without Intracranial Pressure Monitoring (ICP) Monitoring Guidelines N/A
Recruiting NCT03940443 - Differences in Mortality and Morbidity in Patients Suffering a Time-critical Condition Between GEMS and HEMS
Recruiting NCT03937947 - Traumatic Brain Injury Associated Radiological DVT Incidence and Significance Study
Completed NCT04465019 - Exoskeleton Rehabilitation on TBI
Recruiting NCT04530955 - Transitioning to a Valve-Gated Intrathecal Drug Delivery System (IDDS) N/A
Recruiting NCT03899532 - Remote Ischemic Conditioning in Traumatic Brain Injury N/A
Suspended NCT04244058 - Changes in Glutamatergic Neurotransmission of Severe TBI Patients Early Phase 1
Completed NCT03307070 - Adapted Cognitive Behavioral Treatment for Depression in Patients With Moderate to Severe Traumatic Brain Injury N/A
Recruiting NCT04274777 - The Relationship Between Lipid Peroxidation Products From Traumatic Brain Injury and Secondary Coagulation Disorders
Withdrawn NCT04199130 - Cognitive Rehabilitation and Brain Activity of Attention-Control Impairment in TBI N/A
Withdrawn NCT05062148 - Fundamental and Applied Concussion Recovery Modality Research and Development: Applications for the Enhanced Recovery N/A
Withdrawn NCT03626727 - Evaluation of the Efficacy of Sodium Oxybate (Xyrem®) in Treatment of Post-traumatic Narcolepsy and Post-traumatic Hypersomnia Early Phase 1